Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive Phase I/II study of crovalimab (RO7112689) in healthy volunteers and patients with paroxysmal nocturnal hemoglobinuria
jRCT2080223462Phase 2Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2 trial of crovalimab in paroxysmal nocturnal hemoglobinuria (PNH) (3 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoints: Safety and tolerability of crovalimab, Efficacy of crovalimab in PNH and 2 more. Started Feb 2017; status: completed.
02
Drugs
crovalimab
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on jRCT2080223462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223462.